Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide further evidence of the clinical and bacteriological
efficacy of retapamulin in the treatment of subjects with SITL or impetigo due to MRSA.
Subjects aged 2 months and older will be treated with either topical retapamulin for 5 days
or oral linezolid for 10 days. The primary endpoint is the clinical response at follow-up
(7-9 days after the end of therapy) in subjects who have a MRSA infection at baseline. The
primary population is the per-protocol MRSA population. It is anticipated that approximately
500 subjects may be enrolled in order to obtain approximately 105 subjects who have a
baseline MRSA infection.